Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$MYNZ
Key Corporate & Product Development Highlights
Accelerated international commercial activities for ColoAlert, the Company’s highly efficacious and easy-to-use detection test for colorectal cancer (CRC)
Appointed Darin Leigh, former Abbott and Luminex executive, as Chief Commercial Officer
Established partnership with Dante Labs to market ColoAlert in Italy and the United Arab Emirates
Initiated and enrolled the first patient in an international clinical study (ColoFuture) evaluating the integration of novel mRNA biomarkers into ColoAlert – potentially upgrading its technical profile to achieve “gold standard” status for CRC at-home testing
Received supportive feedback from the U.S. Food and Drug Administration (FDA) on ColoAlert’s pre-submission package for its U.S. pivotal clinical trial set to commence in Q4 2022
Achieved multiple preclinical milestones supporting the continued development of PancAlert, a potential first-in-class screening test for pancreatic cancer
Executed a $25.8 million (gross) public follow-on offering
Expanded Strategic Advisory Board of global leaders in molecular diagnostic development and commercialization
“At the outset of 2022, we established ambitious commercial and product development objectives for the year, mostly around our flagship product ColoAlert. I’m pleased to report that we achieved all of our corporate growth goals for the first half period,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “The Company is financially well positioned to maintain momentum as ColoAlert continues to gain impressive commercial traction across Europe and select international territories, and as we ramp up to launch its U.S. pivotal clinical trial by the end of the year.”
$MYNZ Mainz Biomed Reports First Half 2022 Financial Results
https://finance.yahoo.com/news/mainz-biomed-reports-first-half-070100420.html
$MYNZ Mainz Biomed Reports First Half 2022 Financial Results
https://finance.yahoo.com/news/mainz-biomed-reports-first-half-070100420.html
It’s market conditions that every stock is dealing with right now. Smart money is DCAing. Anyone with cash will make huge gains when the market turns back positive
Mainz Biomed Appoints Dr. Douglas Rex to its Medical Advisory Board
https://finance.yahoo.com/news/mainz-biomed-appoints-dr-douglas-070100627.html
$MYNZ Mainz Biomed Appoints Dr. Douglas Rex to its Medical Advisory Board https://finance.yahoo.com/news/mainz-biomed-appoints-dr-douglas-070100627.html
$MYNZ Mainz Biomed Appoints Dr. Douglas Rex to its Medical Advisory Board https://finance.yahoo.com/news/mainz-biomed-appoints-dr-douglas-070100627.html
Awesome bro!
Looking awesome today bro!
Cool bro!
As long as bitcoin keeps moving up I don’t see why not. Miners are back in profitable territory once again. :D
$NBIO Nascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional Patent
https://finance.yahoo.com/news/nascent-biotech-receives-notice-allowance-120000617.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via
$NBIO Nascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional Patent
https://finance.yahoo.com/news/nascent-biotech-receives-notice-allowance-120000617.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via
This is an awesome milestone for the company!
Exactly bro! Just accumulate for now. When she’s ready to roll she will break to the upside where it will be almost impossible to catch
$MYNZ ColoAlert, Mainz Biomed's flagship product, combines the advantages of both methods.
https://www.l3opptrk.com/3J67C1/3T3PPKJ/
$MYNZ ColoAlert, Mainz Biomed's flagship product, combines the advantages of both methods.
https://www.l3opptrk.com/3J67C1/3T3PPKJ/
$MYNZ ColoAlert, Mainz Biomed's flagship product, combines the advantages of both methods.
https://www.l3opptrk.com/3J67C1/3T3PPKJ/
$BBBT Legalized Cann-a-bis Is Creating a New Market For Non-Toxic Pesticides...and It's Pretty Darn Big
https://www.l3opptrk.com/3J67C1/3SZXZ4B/
$BBBT Legalized Cann-a-bis Is Creating a New Market For Non-Toxic Pesticides...and It's Pretty Darn Big
https://www.l3opptrk.com/3J67C1/3SZXZ4B/
$BBBT Legalized Cann-a-bis Is Creating a New Market For Non-Toxic Pesticides...and It's Pretty Darn Big
https://www.l3opptrk.com/3J67C1/3SZXZ4B/
$MYNZ As of June 10th, 2022 company insiders are still sitting on over 23% of available shares–what do they know that you don’t?
https://www.l3opptrk.com/3J67C1/3T3PPKJ/
$MYNZ As of June 10th, 2022 company insiders are still sitting on over 23% of available shares–what do they know that you don’t?
https://www.l3opptrk.com/3J67C1/3T3PPKJ/
$BBBT A Sub-Penny Company With Exceptional Potential.
https://www.l3opptrk.com/3J67C1/3SZXZ4B/
$BBBT A Sub-Penny Company With Exceptional Potential.
https://www.l3opptrk.com/3J67C1/3SZXZ4B/
$BBBT A Sub-Penny Company With Exceptional Potential.
https://www.l3opptrk.com/3J67C1/3SZXZ4B/
$MYNZ With the global economic impact of cancer costing over $1.16 trillion annually…
https://www.l3opptrk.com/3J67C1/3T3PPKJ/
$MYNZ With the global economic impact of cancer costing over $1.16 trillion annually…
https://www.l3opptrk.com/3J67C1/3T3PPKJ/
$MYNZ With the global economic impact of cancer costing over $1.16 trillion annually…
https://www.l3opptrk.com/3J67C1/3T3PPKJ/
$BBBT A BETTER WAY TO PLAY THE EXPLOSIVE CANN-A-BIS MARKET IN 2022?
https://www.l3opptrk.com/3J67C1/3SZXZ4B/
$BBBT A BETTER WAY TO PLAY THE EXPLOSIVE CANN-A-BIS MARKET IN 2022?
https://www.l3opptrk.com/3J67C1/3SZXZ4B/
$BBBT A BETTER WAY TO PLAY THE EXPLOSIVE CANN-A-BIS MARKET IN 2022?
https://www.l3opptrk.com/3J67C1/3SZXZ4B/
WHAT COULD FDA APPROVAL MEAN FOR MAINZ BIOMED (NASDAQ: $MYNZ ) AND ITS NEW BLOCKBUSTER EARLY DETECTION TEST?
https://www.l3opptrk.com/3J67C1/3T3PPKJ/
WHAT COULD FDA APPROVAL MEAN FOR MAINZ BIOMED (NASDAQ: $MYNZ ) AND ITS NEW BLOCKBUSTER EARLY DETECTION TEST?
https://www.l3opptrk.com/3J67C1/3T3PPKJ/
WHAT COULD FDA APPROVAL MEAN FOR MAINZ BIOMED (NASDAQ: $MYNZ ) AND ITS NEW BLOCKBUSTER EARLY DETECTION TEST?
https://www.l3opptrk.com/3J67C1/3T3PPKJ/
$BBBT A Sub-Penny Company With Exceptional Potential.
https://www.l3opptrk.com/3J67C1/3SZXZ4B/
$BBBT A Sub-Penny Company With Exceptional Potential.
https://www.l3opptrk.com/3J67C1/3SZXZ4B/
$BBBT A Sub-Penny Company With Exceptional Potential.
https://www.l3opptrk.com/3J67C1/3SZXZ4B/
$MYNZ With the global economic impact of cancer costing over $1.16 trillion annually…
https://www.l3opptrk.com/3J67C1/3T3PPKJ/
$MYNZ With the global economic impact of cancer costing over $1.16 trillion annually…
https://www.l3opptrk.com/3J67C1/3T3PPKJ/